Please ensure Javascript is enabled for purposes of website accessibility

Could Novavax Have a Clinical Trial Mutiny on Its Hands?

By Keith Speights and Brian Orelli, PhD - Updated Jun 25, 2021 at 2:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The short answer: Not likely.

No proof of vaccination, no travel. That's the reality for people in the United Kingdom. But for individuals in Novavax's (NVAX 2.80%) U.K. late-stage study of its COVID-19 vaccine, this reality has become a problem. Some study participants have even reportedly threatened to drop out of the clinical trial. In this Motley Fool Live video recorded on May 26, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Novavax could have a clinical trial mutiny on its hands.

Keith Speights: The Guardian, which is a U.K. news publication, recently reported, Brian, that some participants in Novavax's phase 3 clinical trial that is being conducted in the United Kingdom, that some participants are threatening to drop out of the study. The problem apparently is that they can't prove that they're fully vaccinated in the National Health Services app that's required for traveling to other European countries. How big of an issue do you think this might be for Novavax?

Brian Orelli: I don't really see it as a big issue at all. First of all, the company is working with the government to get them listed in the app. Then second, at this point, everybody in the state has already been vaccinated so it was one of those crossover things. There was either a placebo group or vaccine group, and then after they released the efficacy data, then they switched everybody, and people with a placebo got vaccine and people with a vaccine got placebo.

Everybody has been vaccinated at this point. All they're looking at is safety, they can't look at efficacy anymore because everybody has the vaccine. If a few people drop out, I don't see that big of a deal. Even if a lot of people drop out, they're just trying to gather more safety data, I don't think it's the end of the world.

Speights: I wondered if this was much ado about nothing, but sometimes the controversy sells and to have some participants threaten to drop out certainly was newsworthy, I guess.

Orelli: I think it's newsworthy for the news, I don't think it's newsworthy for investors.

Speights: Right. Good point.

Brian Orelli, PhD owns shares of Novavax. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$41.47 (2.80%) $1.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.